TESARO™

TESARO, Inc.
Investor Relations Department
1000 Winter St., Ste. 3300
Waltham, MA 02451
United States

Visit IR website ↗
Sign-up for Email alerts ↗

NASDAQ: TSRO

Last Trade:	154.47
Trade Time:	4:00 PM ET 5/22/2017
Change:	2.13 ⬆ (+1.398%)
Day Range	149.57 - 155.29
52-Week Range	36.71 - 192.94
Volume	593,997

Company Profile

Founded in 2010, TESARO is a publicly-traded oncology focused company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates. Upon successful development and regulatory approval of any of our product candidates, TESARO intends to make them available to cancer patients in North America, Europe and China through its own commercialization efforts and to establish a network of licensees and distributors in other geographic areas. For more information... (more)

Stock Performance

Press Releases   [View all]

5/22/2017
National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community

5/11/2017
TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer

5/09/2017
TESARO Announces First-Quarter 2017 Operating Results

5/01/2017
TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA

4/27/2017
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042

Upcoming Events   [View all]

6/03/2017 6:15 PM CT
TESARO Investor Briefing at ASCO

Financials   [View all]

2/28/2017
Annual Report (10-K)

4/07/2017
Proxy Statement (DEF 14A)

5/09/2017
Quarterly Report (10-Q)

11/04/2016
Quarterly Report (10-Q)

8/05/2016
Quarterly Report (10-Q)